AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
GET MORE AI-GENERATED SIGNALS: February 15, 2025, 04:28 am ET, BY Thomas H. Kee Jr- Editor, Stock Traders Daily| Editor: ...
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB) been one of those stocks this year?